Active ingredientCisplatinCat. No. P-C176-001CAS 15663-27-1Family · Pharmaceutical analytical standards
Cisplatin
A platinum-based chemotherapy drug, first synthesised in the mid-19th century by Italian chemist Michele Peyrone: its anticancer activity was discovered in the 1960s and in the United States it was approved in 1978 for testicular and ovarian cancer. This family brings together the active ingredient and other impurities.
Did you know?It was found by chance: Barnett Rosenberg passed current between platinum electrodes in a culture of Escherichia coli and the bacteria stopped dividing. The cause was not the current, but a platinum compound from the electrodes.
Go to the active ingredient →Active ingredientCisplatinCat. No. P-C176-001CAS 15663-27-1
Impuritycis-Diammine-Diiodo Platinum IICat. No. P-C176-002CAS 13841-96-8
ImpurityMonoaquacisplatinumCat. No. P-C176-003CAS 53861-42-0
Impuritycis-Diaquodiammineplatinum(II) dinitrateCat. No. P-C176-004CAS 13601-02-0
ImpurityPotassium Tetrachloroplatinum(II)Cat. No. P-C176-006CAS 10025-99-7
ImpurityPotassium TrichloroammineplatinateCat. No. P-C176-007CAS 13820-91-2
ImpurityTransplatinCat. No. P-C176-008CAS 14913-33-8No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Reference substanceCisplatin CRSEDQM code C2210000Family CisplatinImpurityCisplatin impurity A CRSEDQM code Y0001018Family CisplatinImpurityCisplatin impurity B CRSEDQM code Y0001019Family CisplatinNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.